Ornithine phenylacetate

Drug Profile

Ornithine phenylacetate

Alternative Names: L-Ornithine phenylacetate; OCR-002; OP; Ornithine hydrochloride/sodium phenylacetate; Sodium phenylacetate/ornithine hydrochloride; UCL-L1V

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator University College London
  • Developer Ocera Therapeutics
  • Class Basic amino acids; Diamino amino acids; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules
  • Mechanism of Action Aminohydrolase modulators; Ammonia scavengers; NF-kappa B modulators; Nitric oxide synthase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy; Liver failure
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Hepatic encephalopathy
  • Phase II Liver failure
  • Preclinical Non-alcoholic fatty liver disease

Most Recent Events

  • 12 Apr 2017 Preclinical trials in Non-alcoholic fatty liver disease in USA (IV)
  • 12 Apr 2017 Pharmacodynamics data from a preclinical trial in Non-alcoholic fatty liver disease released by Ocera Therapeutics
  • 10 Mar 2017 Ocera Therapeutics announces intention to meet with the US FDA to discuss phase III development plan for Ornithine phenylacetate in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top